Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.

Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.

PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.

2.

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet].

Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Pappas M, Zakher B.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Dec.

3.

Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.

Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ.

Gynecol Oncol. 2000 Aug;78(2):148-51.

PMID:
10926794
4.

Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.

Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O, Rennert G.

Ann Oncol. 2011 Apr;22(4):964-6. doi: 10.1093/annonc/mdq460. Epub 2010 Oct 5.

5.

Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.

Manchanda R, Patel S, Antoniou AC, Levy-Lahad E, Turnbull C, Evans DG, Hopper JL, Macinnis RJ, Menon U, Jacobs I, Legood R.

Am J Obstet Gynecol. 2017 Nov;217(5):578.e1-578.e12. doi: 10.1016/j.ajog.2017.06.038. Epub 2017 Jul 6.

PMID:
28690137
6.

Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility [Internet].

Nelson HD, Huffman LH, Fu R, Harris EL, Walker M, Bougatsos C.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Sep.

8.

BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.

Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA.

Am J Hum Genet. 2000 Apr;66(4):1259-72. Epub 2000 Mar 16.

9.

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T.

Am J Hum Genet. 1997 Mar;60(3):505-14.

10.

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.

Roa BB, Boyd AA, Volcik K, Richards CS.

Nat Genet. 1996 Oct;14(2):185-7.

PMID:
8841191
11.

Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel.

Rennert G, Dishon S, Rennert HS, Fares F.

Eur J Cancer Prev. 2005 Aug;14(4):357-61.

PMID:
16030426
12.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

13.

Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.

Robson M, Dabney MK, Rosenthal G, Ludwig S, Seltzer MH, Gilewski T, Haas B, Osborne M, Norton L, Gilbert F, Offit K.

Genet Test. 1997;1(1):47-51.

PMID:
10464625
14.

Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.

Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.

J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.

15.

Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.

Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):379. doi: 10.1093/jnci/dju379. Print 2015 Jan.

16.

Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.

Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M.

Br J Cancer. 1998 Sep;78(6):771-3.

17.

Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.

Patel S, Legood R, Evans DG, Turnbull C, Antoniou AC, Menon U, Jacobs I, Manchanda R.

Am J Obstet Gynecol. 2017 Dec 26. pii: S0002-9378(17)32720-5. doi: 10.1016/j.ajog.2017.12.221. [Epub ahead of print]

PMID:
29288066
18.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

19.

Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.

Eccles DM, BalmaƱa J, Clune J, Ehlken B, Gohlke A, Hirst C, Potter D, Schroeder C, Tyczynski JE, Gomez Garcia EB.

Adv Ther. 2016 Feb;33(2):129-50. doi: 10.1007/s12325-016-0281-1. Epub 2016 Jan 25. Review.

PMID:
26809252
20.

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73.

Supplemental Content

Support Center